Core Viewpoint - Guangji Pharmaceutical (000952.SZ) expects a net profit attributable to shareholders of -518 million to -399 million yuan for 2025, compared to -295.29 million yuan in the same period last year, indicating a continued operational loss due to intensified market competition and low product prices [1] Group 1: Financial Performance - The company anticipates a net profit of -527.5 million to -408.5 million yuan after deducting non-recurring gains and losses [1] - The previous year's net profit was -295.29 million yuan, highlighting a worsening financial outlook [1] Group 2: Operational Challenges - The company is facing ongoing operational losses due to prolonged low sales prices of its main products and insufficient capacity utilization [1] - Several subsidiaries have not shown effective improvement in their operational status, continuing to incur losses [1] Group 3: Asset Impairment - There are significant signs of asset impairment due to insufficient production line operation rates and declining market prices [1] - The company plans to make impairment provisions for assets showing signs of impairment, with the final impairment amount to be determined by professional assessments and audits [1]

Core Viewpoint - Guangji Pharmaceutical expects a net profit loss attributable to shareholders of between 518 million yuan and 399 million yuan for the fiscal year 2025, compared to a loss of 295 million yuan in the same period last year [1] Group 1: Financial Performance - The company is projected to experience a significant increase in net losses, indicating a worsening financial situation [1] - The anticipated loss range for 2025 represents a deterioration compared to the previous year's loss [1] Group 2: Market Conditions - The pharmaceutical industry is facing intensified market competition, which has adversely affected the company's pricing power [1] - The sales prices of the company's main products have remained low and have not shown signs of recovery during the reporting period [1] Group 3: Operational Performance - The company's capacity utilization and overall operational performance have not met expectations, contributing to ongoing operational losses [1]